Hypoxic Ischemic Encephalopathy Market Size is anticipated to increase during the study period, 2019-2032 | Key Companies: - ReAlta Life Sciences, Hope Biosciences, and Others.

"Growth of the Hypoxic Ischemic Encephalopathy Market is expected to be mainly driven by a rise in the number of prevalent cases, and rise in the usage of current treatment options"

The Hypoxic Ischemic Encephalopathy market report provides current treatment practices, Hypoxic Ischemic Encephalopathy emerging drugs, Hypoxic Ischemic Encephalopathy market share of the individual therapies, current and forecasted Hypoxic Ischemic Encephalopathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hypoxic Ischemic Encephalopathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hypoxic Ischemic Encephalopathy market.

Key takeaways from the Hypoxic Ischemic Encephalopathy Market Research Report

• The increase in market size is a direct consequence of an increase in R&D activity and increasing population Hypoxic Ischemic Encephalopathy in the 7MM.

• According to secondary findings, clinically, male infants are more vulnerable to neonatal HIE and suffer more long-term deficits than female. Clinical data shows that females have a substantial advantage over males, among infants at risk for HIE.

• As per the HIE Help Center, Neonatal HIE is estimated to occur in about 1.5 per 1,000 live births. Among infants with moderate HIE, 10-20% develop minor neurological conditions, and 30-50% develop more serious complications. For infants with severe HIE, there is a 25-50% mortality rate. Deaths most often occur in the first few days after birth. Of babies that survive, roughly 80% develop serious complications.

• The leading Hypoxic Ischemic Encephalopathy Market Companies includes ReAlta Life Sciences, Hope Biosciences, and Others.

• Promising Hypoxic Ischemic Encephalopathy Pipeline Therapies includes RLS-0071, HB-adMSCs, and others.

Discover which therapies are expected to grab the major Hypoxic Ischemic Encephalopathy Market share, click here for Hypoxic Ischemic Encephalopathy Market Research Report @ https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in Hypoxic Ischemic Encephalopathy Treatment Landscape

• ReAlta Life Sciences is currently evaluating it potential candidate RLS-0071 for the treatment of HIE in neonates. Currently this drug is in the initial phase of clinical development and in February 2020, the US FDA granted Orphan Drug Designation to this drug for HIE treatment. RLS-0071 is the first anti-inflammatory/antioxidant compound studied for HIE. RLS-0071 represents a new treatment approach with a focus on preventing brain damage. RLS-0071 is designed to decrease reperfusion injury via our dual targeting mechanisms of action that inhibits complement activation and innate inflammatory processes and oxidative damage. The first-in-human Phase I clinical data on RLS-0071, demonstrated an excellent safety profile and confirmed target engagement in healthy volunteers. The data were presented at the American Academy of Neurology 2022. In March 2022, the company announced that announced that the US FDA has given clearance of an Investigational New Drug (IND) application for a Phase II clinical trial of RLS-0071 in neonates with hypoxic-ischemic encephalopathy. In June 2022, the US FDA granted Fast Track designation to RLS-0071 for the treatment of hypoxic ischemic encephalopathy. ReAlta plans to initiate a Phase II study with RLS-0071 as a treatment for HIE in 2023.

• Apart from this, Hope Biosciences with the University of Texas Health Science Center is evaluating HB-adMSCs (Hope Biosciences autologous adipose-derived mesenchymal stem cells) in an ongoing Phase I/II trial for the treatment of traumatic brain injury and HIE. This trial is estimated to enroll 24 participants is anticipated to be completed by December 2024. This main objective of this study is to determine the safety of HB-adMSC infusion and treatment effects of HB-adMSC infusion on global gray and/or white matter, as well as structural integrity of GM and WM regions of interest in the corpus callous and corticospinal tracts as measured by fractional anisotropy (FA) and mean diffusivity (MD) in specific regions known to correlate with specific neurocognitive deficits in patients after neurological injury.

• GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), has completed a Phase I trial in healthy volunteers for an additional cannabinoids in the treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE). Under an IND, GW has completed a Phase 1 trial of GWP42003 in healthy volunteers for an intravenous formulation in the treatment of NHIE. It is noteworthy that, GW has received Orphan Drug Designation and Fast Track Designation from the FDA for for the treatment of NHIE. GW has also received Orphan Drug Designation from the EMA for for the treatment of perinatal asphyxia, an alternate term that describes the same condition.

Hypoxic Ischemic Encephalopathy Overview
Hypoxic-ischemic encephalopathy (HIE) is a serious and life-threatening type of newborn brain damage (brain dysfunction) that occurs when the brain doesn't receive enough oxygen and blood flow for a period of time. As the name suggests, Hypoxic means, not enough oxygen; ischemic means not enough blood flow; and encephalopathy means brain disorder.

Hypoxic Ischemic Encephalopathy Epidemiology Segmentation in the 7MM
• Total Hypoxic Ischemic Encephalopathy Incident Cases
• Total Hypoxic Ischemic Encephalopathy Diagnosed Cases
• Total Hypoxic Ischemic Encephalopathy Incident Cases
• Total Hypoxic Ischemic Encephalopathy Treated Cases

Download the report to understand which factors are driving Hypoxic Ischemic Encephalopathy Market Trends, click here for Hypoxic Ischemic Encephalopathy Market Forecast @ https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypoxic Ischemic Encephalopathy Market Insights
Despite a multitude of studies, the ultimate pathogenesis of HIE remains unknown. HIE symptoms can be ambiguous and frequently overlap with other neurologic and metabolic disorders in newborns. Therefore, it is imperative to rule out life-threatening or treatable causes of these symptoms. Treatment can be separated into immediate/hospital management and long-term treatment. In moderate to severe HIE, it is very important that the child is properly monitored and treated.

Hypoxic Ischemic Encephalopathy Treatment Market
For this type of treatment, the baby will be placed on a cooling blanket for three days. Babies are then given medicines to help them rest comfortably and are closely monitored for any signs of discomfort. After the cooling period, the baby will be slowly re-warmed to normal body temperature. Heart rate, breathing patterns and temperature are also monitored very precisely.

Hypoxic Ischemic Encephalopathy Market Dynamics
The dynamics of the Hypoxic Ischemic Encephalopathy market are expected to improve in the next years as a result of the increase in R&D and introduction of new medicines. Key companies such as ReAlta Life Sciences, Hope Biosciences, GW Pharmaceuticals, Chiesi, and others are developing innovative medicines for this indication, which will result in a considerable increase in the market size.

Learn more about the Hypoxic Ischemic Encephalopathy FDA-approved drugs, click here for Hypoxic Ischemic Encephalopathy Treatment Market @ https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hypoxic Ischemic Encephalopathy Market Research Report

• Coverage- 7MM

• Hypoxic Ischemic Encephalopathy Companies- ReAlta Life Sciences, Hope Biosciences, and Others.

• Hypoxic Ischemic Encephalopathy Pipeline Therapies- RLS-0071, HB-adMSCs, and others.

• Hypoxic Ischemic Encephalopathy Market Dynamics: Hypoxic Ischemic Encephalopathy Market Drivers and Barriers

Discover more about Hypoxic Ischemic Encephalopathy Drugs in development, click here for Hypoxic Ischemic Encephalopathy Market Drugs @ https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Hypoxic Ischemic Encephalopathy
3. Competitive Intelligence Analysis for Hypoxic Ischemic Encephalopathy
4. Hypoxic Ischemic Encephalopathy: Market Overview at a Glance
5. Hypoxic Ischemic Encephalopathy: Disease Background and Overview
6. Patient Journey
7. Hypoxic Ischemic Encephalopathy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Hypoxic Ischemic Encephalopathy Unmet Needs
10. Key Endpoints of Hypoxic Ischemic Encephalopathy Treatment
11. Hypoxic Ischemic Encephalopathy Marketed Products
12. Hypoxic Ischemic Encephalopathy Emerging Therapies
13. Hypoxic Ischemic Encephalopathy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Hypoxic Ischemic Encephalopathy Market Outlook
16. Access and Reimbursement Overview of Hypoxic Ischemic Encephalopathy
17. KOL Views
18. Hypoxic Ischemic Encephalopathy Market Drivers
19. Hypoxic Ischemic Encephalopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

To read more about the Hypoxic Ischemic Encephalopathy Market Dynamics of the report, click here for Hypoxic Ischemic Encephalopathy Market Barriers and Drivers @ https://www.delveinsight.com/sample-request/hypoxic-ischemic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.